Literature DB >> 16270046

Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas.

B Martínez-Delgado1, M Cuadros, E Honrado, A Ruiz de la Parte, G Roncador, J Alves, J M Castrillo, C Rivas, J Benítez.   

Abstract

Nuclear factor kappa B (NF-kappaB) is one important pathway in T-cell proliferation and survival. In a previously reported microarray study, we found NF-kappaB pathway genes differentially expressed between peripheral (PTCL) and lymphoblastic lymphomas. Here, we investigated the expression of NF-kappaB pathway genes using cDNA microarrays in a group of 62 PTCL and in reactive lymph nodes. We found two different subgroups of PTCL based on the expression of NF-kappaB pathway genes. One-third of PTCL showed clearly reduced expression of NF-kappaB genes, while the other group was characterized by high expression of these genes. This distinction was found among all T-cell lymphoma categories analyzed (PTCL unspecified, angioimmunoblastic, cutaneous and natural killer/T lymphomas) with the exception of anaplastic lymphomas (ALCL), which were characterized by reduced NF-kappaB expression in anaplastic cells. Quantitative RT-PCR and immunohistochemical analysis of NF-kappaB-p65 protein confirmed these differences among PTCL subgroups. Importantly, we found that differentiation between NF-kappaB-positive and -negative PTCL could be of clinical interest. The expression profile associated to reduced expression of NF-kappaB genes was significantly associated with shorter survival of patients and seems to be an independent prognostic factor in a multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16270046     DOI: 10.1038/sj.leu.2403960

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  33 in total

Review 1.  New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.

Authors:  Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

2.  Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines, and peripheral T-cell lymphoma.

Authors:  Sarah H Beachy; Masahiro Onozawa; Yang Jo Chung; Chris Slape; Sven Bilke; Princy Francis; Marbin Pineda; Robert L Walker; Paul Meltzer; Peter D Aplan
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

3.  The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; N Sertac Kip; Xiaoming Xing; Yu Zeng; Zhi-Zhang Yang; Jeong-Heon Lee; Luciana L Almada; Sherine F Elsawa; Ryan A Knudson; Mark E Law; Rhett P Ketterling; Julie M Cunningham; Yanhong Wu; Matthew J Maurer; Megan M O'Byrne; James R Cerhan; Susan L Slager; Brian K Link; Julie C Porcher; Deanna M Grote; Diane F Jelinek; Ahmet Dogan; Stephen M Ansell; Martin E Fernandez-Zapico; Andrew L Feldman
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

Review 4.  Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.

Authors:  Waseem Lone; Aisha Alkhiniji; Jayadev Manikkam Umakanthan; Javeed Iqbal
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

5.  Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.

Authors:  Javeed Iqbal; George Wright; Chao Wang; Andreas Rosenwald; Randy D Gascoyne; Dennis D Weisenburger; Timothy C Greiner; Lynette Smith; Shuangping Guo; Ryan A Wilcox; Bin Tean Teh; Soon Thye Lim; Soon Yong Tan; Lisa M Rimsza; Elaine S Jaffe; Elias Campo; Antonio Martinez; Jan Delabie; Rita M Braziel; James R Cook; Raymond R Tubbs; German Ott; Eva Geissinger; Philippe Gaulard; Pier Paolo Piccaluga; Stefano A Pileri; Wing Y Au; Shigeo Nakamura; Masao Seto; Francoise Berger; Laurence de Leval; Joseph M Connors; James Armitage; Julie Vose; Wing C Chan; Louis M Staudt
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

6.  Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition.

Authors:  M R Sapienza; F Fuligni; C Agostinelli; C Tripodo; S Righi; M A Laginestra; A Pileri; M Mancini; M Rossi; F Ricci; A Gazzola; F Melle; C Mannu; F Ulbar; M Arpinati; M Paulli; T Maeda; D Gibellini; L Pagano; N Pimpinelli; M Santucci; L Cerroni; C M Croce; F Facchetti; P P Piccaluga; S A Pileri
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

Review 7.  New molecular insights into peripheral T cell lymphomas.

Authors:  Stefano A Pileri; Pier Paolo Piccaluga
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

8.  Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma.

Authors:  Javeed Iqbal; Dennis D Weisenburger; Timothy C Greiner; Julie M Vose; Timothy McKeithan; Can Kucuk; Huimin Geng; Karen Deffenbacher; Lynette Smith; Karen Dybkaer; Shigeo Nakamura; Masao Seto; Jan Delabie; Francoise Berger; Florence Loong; Wing Y Au; Young-Hyeh Ko; Ivy Sng; James Olen Armitage; Wing C Chan
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113

9.  Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.

Authors:  Shuyan Liu; Zhengang Yuan; Chunyang Zhang; Weijun Fu; Jian Hou
Journal:  Oncol Lett       Date:  2012-05-21       Impact factor: 2.967

10.  CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.

Authors:  Bettina Bisig; Aurélien de Reyniès; Christophe Bonnet; Pierre Sujobert; David S Rickman; Teresa Marafioti; Georges Delsol; Laurence Lamant; Philippe Gaulard; Laurence de Leval
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.